A study using paired ovarian carcinoma cell lines with different cisplatin sensitivities showed that SOCE participates in therapy resistance through elevated Orai1/STIM1 expressions and SOCE activity, accompanied by increased AKT activity [38]. This evidence concerns the gene STIM1 and ovarian carcinoma.